--- title: "Pre-market trend | Immunovant (IMVT) surged 35% on May 20, can it continue after the breakout?" type: "News" locale: "en" url: "https://longbridge.com/en/news/287116452.md" description: "Yesterday, Immunovant's stock price surged by 35.26%, with a trading volume of USD 663 million, reaching a recent record high, and the market's enthusiasm for this biotech stock was nearly frenzied. The MACD daily line formed a bullish signal above the zero axis, combined with such an astonishing single-day increase and high trading volume, is typically seen as a strong signal for establishing a phase trend reversal. The stock price broke through the consolidation range of the previous weeks, with the 5-day and 10-day moving averages left far behind, indicating an explosive release of short-term bullish momentum. Such a level of volume breakout in the biotech sector often corresponds to significant catalyst-driven events. From an industry perspective, the capital activity in the biotech sector has significantly increased recently, with Roivant Sciences also rising sharply by 14.89% yesterday, as market attention on innovative drug pipelines continues to grow. Immunovant focuses on FcRn antibody therapy, and its clinical progress in autoimmune diseases may be the core driving force behind this surge. Currently, the overall risk appetite in the U.S. stock market is warming up, with the S&P 500 ETF rising by 1.02%, and both the technology and biotech sectors strengthening, providing a favorable external environment for small and mid-cap growth stocks. Although the Federal Reserve's meeting minutes were hawkish, the market chose to pursue growth logic in the short term. Technically, yesterday's massive long bullish line itself constituted a strong short-term support reference, but the 35% single-day increase also indicates that short-term technical indicators are severely overbought. If trading volume quickly shrinks after the market opens today, the probability of a pullback after a high will significantly increase" datetime: "2026-05-21T13:00:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287116452.md) - [en](https://longbridge.com/en/news/287116452.md) - [zh-HK](https://longbridge.com/zh-HK/news/287116452.md) --- # Pre-market trend | Immunovant (IMVT) surged 35% on May 20, can it continue after the breakout? Yesterday, Immunovant's stock price surged by 35.26%, with a trading volume of $663 million, reaching a recent record high, and the market's enthusiasm for this biotech stock was nearly frenzied. The MACD daily line formed a bullish signal above the zero axis, combined with such an astonishing single-day increase and high trading volume, which is typically seen as a strong signal for establishing a phase trend reversal. The stock price broke through the consolidation range of the previous weeks, with the 5-day and 10-day moving averages left far behind, indicating an explosive release of short-term bullish momentum. Such a level of volume breakout in the biotech sector often corresponds to significant catalyst-driven events. From an industry perspective, the activity level of funds in the biotech sector has significantly increased recently, with Roivant Sciences also rising by 14.89% yesterday, as market attention towards innovative drug pipelines continues to grow. Immunovant focuses on the FcRn antibody therapy field, and its clinical progress in autoimmune diseases may be the core driving force behind this surge. Currently, the overall risk appetite in the U.S. stock market is warming up, with the S&P 500 ETF rising by 1.02%, and both the technology and biotech sectors strengthening together, providing a favorable external environment for small and mid-cap growth stocks. Although the Federal Reserve's meeting minutes were hawkish, the market chose to pursue growth logic in the short term. From a technical perspective, yesterday's massive long bullish candle itself constituted a strong short-term support reference, but the 35% single-day increase also indicates that short-term technical indicators are severely overbought. If trading volume quickly shrinks after the market opens today, the probability of a pullback after a peak will significantly increase. Attention should be paid to whether there are sustained large buy orders during the day to maintain price stability, as well as the performance of the biotech sector index. The short-term trend reference is extremely bullish, but the violent fluctuations after such a surge are almost a certainty. The high volatility characteristics of biotech stocks make short-term trends difficult to extrapolate linearly, and investors need to fully recognize the bidirectional risks of significant fluctuations. _This article only provides technical analysis and market information for reference and does not constitute any investment advice. The market carries uncertainties, and investors should make independent decisions based on their own circumstances._ ### Related Stocks - [IMVT.US](https://longbridge.com/en/quote/IMVT.US.md) - [ROIV.US](https://longbridge.com/en/quote/ROIV.US.md) - [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md) - [SPY.US](https://longbridge.com/en/quote/SPY.US.md) ## Related News & Research - [These Analysts Increase Their Forecasts On Immunovant After Q4 Results](https://longbridge.com/en/news/287250728.md) - [Assessing Immunovant (IMVT) Valuation After Strong IMVT-1402 Data And Refocused Pipeline Strategy](https://longbridge.com/en/news/287221923.md) - [Immunovant Posts Wider FY26 Loss, Advances IMVT-1402 Pipeline; Stock Up](https://longbridge.com/en/news/287065251.md) - [Immunovant reports $147.9M quarterly net loss, $902.1M cash as of Mar 31, 2026](https://longbridge.com/en/news/287056202.md) - [Immunovant (NASDAQ:IMVT) Stock Price Down 6.4% on Disappointing Earnings](https://longbridge.com/en/news/287244359.md)